Gubra A/S

Copenhagen Stock Exchange GUBRA.CO

Gubra A/S Revenue for the year ending December 31, 2023: USD 30.34 M

Gubra A/S Revenue is USD 30.34 M for the year ending December 31, 2023, a 6.06% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Gubra A/S Revenue for the year ending December 31, 2022 was USD 28.61 M, a -26.68% change year over year.
  • Gubra A/S Revenue for the year ending December 31, 2021 was USD 39.02 M, a 38.27% change year over year.
  • Gubra A/S Revenue for the year ending December 31, 2020 was USD 28.22 M.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Copenhagen Stock Exchange: GUBRA.CO

Gubra A/S

CEO Mr. Henrik Blou
IPO Date April 4, 2023
Location Denmark
Headquarters Hørsholm Kongevej 11B
Employees 235
Sector Health Care
Industries
Biotechnology Pharmaceuticals Research & Consulting
Description

Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.

StockViz Staff

January 15, 2025

Any question? Send us an email